BMS-813160

InvivoChem Cat #:V3488CAS #:1286279-29-5Purity >=98%

Description: BMS-813160 is a novel, potent, selective and dual CCR2/CCR5 antagonist with potential immunomodulating and antineoplastic activities. It is the first dual CCR2/CCR5 antagonist that has entered clinical trials for cardiovascular disease. BMS-813160 specifically binds and prevents the activation of both CCR2 and CCR5. This inhibits the activation of CCR2/CCR5-mediated signal transduction pathways and may inhibit inflammatory processes, angiogenesis, tumor cell migration, tumor cell proliferation and invasion.

References: Expert Opin Ther Pat. 2011 Dec; 21(12):1919-24.

-20C for 3 years in powder form

Synonym: BMS-813160; BMS813160; BMS 813160
Chemical Name: N-[(1R, 2S, 5R)-5-[(1, 1-Dimethylethyl)amino]-2-[(3S)-3-[[7-(1, 1-dimethylethyl)pyrazolo[1, 5-a]-1, 3, 5-triazin-4-yl]amino]-2-oxo-1-pyrrolidinyl]cyclohexyl]acetamide
InChi Key: CMVHFGNTABZQJU-HCXYKTFWSA-N
InChi Code: InChI=1S/C25H40N8O2/c1-15(34)28-18-12-16(30-25(5, 6)7)8-9-19(18)32-11-10-17(22(32)35)29-23-27-14-26-21-13-20(24(2, 3)4)31-33(21)23/h13-14, 16-19, 30H, 8-12H2, 1-7H3, (H, 28, 34)(H, 26, 27, 29)/t16-, 17+, 18-, 19+/m1/s1
SMILES Code: CC(N[CH]1[CH](N2C([CH](NC3=NC=NC4=CC(C(C)(C)C)=NN43)CC2)=O)CC[CH](NC(C)(C)C)C1)=O